Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:URGN

Urogen Pharma Q2 2026 Earnings Report

Urogen Pharma logo
$40.23 +2.20 (+5.78%)
Closing price 04:00 PM Eastern
Extended Trading
$39.86 -0.36 (-0.91%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Urogen Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Urogen Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$62.16 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Urogen Pharma Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
10:00AM ET

Conference Call Resources

Urogen Pharma Earnings Headlines

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
July 8 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324037/0/en/urogen-announces-fda-clearance-of-the-ind-for-ugn-501-an-investigational-next-generation-oncolytic-virus-for-non-muscle-invasive-bladder-cancer.html
Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Analysts
July 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30877758
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
July 9 at 1:00 AM  |  Investors Alley (Ad)
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
June 30, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/30/is-urogen-pharma-a-stock-to-sell-after-its-chief-medical-officer-let-go-of-10-000-shares/
UroGen Shareholders Approve Governance, Compensation and Auditor Changes
June 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/urogen-shareholders-approve-governance-compensation-and-auditor-changes?utm_source=marketbeat.com&utm_medium=referral
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
June 14, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/06/14/is-urogen-pharma-a-stock-to-sell-after-its-chief-medical-officer-unloaded-5-222-shares/
See More Urogen Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Urogen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Urogen Pharma and other key companies, straight to your email.

About Urogen Pharma

Urogen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer. Jelmyto represents the first FDA-approved therapy for this indication, offering a minimally invasive, kidney-sparing alternative to surgery. Beyond Jelmyto, UroGen’s pipeline includes UGN-102, an investigational mitomycin solution under study for interstitial cystitis/bladder pain syndrome, and earlier-stage programs targeting other urologic and ophthalmic conditions leveraging the RTGel platform.

UroGen markets its products primarily in the United States and is pursuing regulatory submissions in Europe and other global regions. The company’s management team is led by Co-Founder and Chief Executive Officer Tomer Kariv, supported by Chief Operating Officer Vas Narasimhan and Chief Medical Officer Philip Isaacs, among others. UroGen collaborates with key opinion leaders in urology to advance its clinical programs and expand patient access to novel in-office therapies.

View Urogen Pharma Profile
Earnings Tools